[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) reported that its Chief Executive Officer and director exercised stock options for 24,082 shares of common stock on 11/21/2025 at an exercise price of $0.54 per share.

Following this transaction, the CEO directly holds 655,387 shares of Mineralys common stock. The filing also clarifies that the option’s exercise price was previously shown as $0.53 per share due to a rounding error in an earlier Form 3, and notes that the option vested 25% on March 12, 2022, with the remainder vesting in 36 substantially equal monthly installments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD,

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		M		24,082	A	$0.54	655,387	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.54(1)	11/21/2025		M			24,082	(2)	03/11/2031	Common Stock	24,082	$0	0	D

Explanation of Responses:

1. Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

2. The stock option vested with respect to 25% of the underlying shares on March 12, 2022 and the remaining shares in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mineralys Therapeutics (MLYS) disclose in this Form 4?

The company reported that its Chief Executive Officer and director exercised stock options for 24,082 shares of common stock at an exercise price of $0.54 per share on 11/21/2025.

How many Mineralys (MLYS) shares does the CEO own after this transaction?

After the reported option exercise, the CEO beneficially owns 655,387 shares of Mineralys Therapeutics common stock in direct ownership.

What type of transaction did the Mineralys CEO report?

The CEO reported an option exercise (coded "M") converting 24,082 stock options with a $0.54 exercise price into the same number of common shares.

Was there any correction to previously reported information for MLYS?

Yes. The filing explains that the option’s exercise price was originally reported as $0.53 per share due to a rounding error on a prior Form 3 and clarifies the correct price is $0.54 per share.

How did the Mineralys CEO’s stock option vest?

The option vested as to 25% of the underlying shares on March 12, 2022, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Does this Form 4 indicate any remaining options for the reported grant?

No. The table shows 0 derivative securities remaining beneficially owned for this specific stock option after the 24,082 options were exercised.